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Abstract 
Achondroplasia is a heritable disorder of endochondral bone formation characterized by 
disproportionate short stature. Osteogenesis imperfecta is a heritable bone and connective tissue 
disorder characterized by bone fragility. To investigate bone morphology of these groups, we 
retrospectively reviewed 169 de-identified bone age films from 20 individuals with achondroplasia, 39 
individuals with osteogenesis imperfecta and 37 age- and sex-matched controls (matched to historical 
measurements from the Bolton-Brush Collection). We calculated robustness (Tt.Ar/Le) and relative 
cortical area (Ct.Ar/Tt.Ar) from measurements of the second metacarpal, which reflect overall bone 
health. Relative cortical area is a significant predictor of fracture risk and correlates with robustness at 
other sites. Individuals with osteogenesis imperfecta had relative cortical area values above and 
robustness values below that of the control population. Bisphosphonate treatment did not significantly 
impact either robustness or relative cortical area. In contrast to that reported in the unaffected 
population, there was no sexual dimorphism found in osteogenesis imperfecta robustness or relative 
cortical area. We suggest that the underlying collagen abnormalities in osteogenesis imperfecta override 
sex-specific effects. Individuals with achondroplasia had robustness values above and relative cortical 
area values below that of the control population. Sexual dimorphism was found in achondroplasia 
robustness and relative cortical area values. Clinical significance: Identifies morphologic trends in two 
distinct skeletal dysplasia populations (osteogenesis imperfecta and achondroplasia) to better 
understand development of bone robusticity and slenderness in humans. Understanding these patterns 
of bone morphology is important to predict how individuals will respond to treatment and to increase 
treatment effect.  
Key words: Achondroplasia, Osteogenesis Imperfecta, Bone Robustness, Bone Morphology, 
Bisphosphonate Treatment  
Introduction 
Variation in morphologic parameters (e.g. bone length and width) contributes to the 
stiffness and strength of the skeleton. Robusticity (total area/bone length) is a trait that describes 
the relationship between transverse expansion and longitudinal growth in long bones (i.e. 
expansion at the growth plate versus periosteal growth)1. The second metacarpal, which has been 
used to determine overall bone health since the 1960s2, has multiple muscle attachments that 
apply sufficient forces to establish mechanically functional structures with varying robustness 
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shown to be a significant predictor of fracture risk at the hip4 and vertebrae5 and its robustness 
has been correlated with that at other sites, i.e. femur and tibia 6, 7. 
Ideally, bones which fall towards the very robust end of the spectrum compensate by 
having a proportionally thinner cortex to minimize mass3. Therefore, robust bones should have a 
low mineral content. Bones which fall toward the narrow or slender end of the external size 
spectrum compensate by having a proportionally thicker cortex to maximize stiffness and 
strength. Therefore, slender bones should have a higher mineral content. The relationship 
between external bone size and relative cortical area and tissue-mineral density is an adaptive 
biological process that involves bone cells adjusting traits (e.g., cortical area, mineralization) in a 
highly coordinated manner so the resultant set of traits has sufficient stiffness to support the 
loads incurred during daily activities (e.g., walking, running, standing, sitting)1. 
We postulate that the adaptation process during growth varies in fundamentally different 
ways among individuals, which results in the acquisition of specific sets of traits that are 
predictable based on bone robustness. Because homeostatic buffering mechanisms during growth 
control the degree of compensation that can be expressed in a population, we expect that 
genetically heterogeneous individuals would not show random trait sets (length, external size, 
internal size), but rather a narrow range of functionally adapted sets of traits. This has been 
confirmed in a recent study using hand radiographs purchased from the Bolton-Brush collection. 
The Bolton-Brush collection includes 330 longitudinally acquired hand radiographs from 24 
healthy white girls and 31 healthy white boys collected in the 1930s in Cleveland, OH. 8 That 
research demonstrated that the inter-individual variation in bone robustness was largely 
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more slender metacarpals with proportionally thicker cortices compared with prepubertal boys. 
Boys and girls with robust diaphyses had proportionally thinner cortices, thereby minimizing 
overall mass, whereas children with slender diaphyses had proportionally thicker cortices to 
maximize stiffness8 consistent with weight-bearing long bones1. 
Finding a consistent pattern of trait sets across a population is important, because it 
means that individuals within this population share a common biological control which regulates 
functional adaptation. Further, finding a consistent pattern of trait sets across a population 
suggests that we can use these biomechanically-based methods to identify, in a new way, disease 
states or treatments that potentially alter the development of bone strength.  
Specifically, understanding the biological factors and variation in these parameters in two 
disparate skeletal dysplasias should allow a better understanding of the inter-individual variation 
in biologic processes that establish mechanical function during growth and development in a 
non-dysplastic population. The skeletal dysplasias comprise a clinically and genetically 
heterogeneous group of over 400 disorders associated with abnormal bone and cartilage growth 
and development9. The two skeletal dysplasias in this study are achondroplasia and osteogenesis 
imperfecta. We selected these diagnoses because of their relatively high prevalence, 
comparatively different clinical findings, and distinct skeletal phenotypes.    
Achondroplasia (ACH) is an autosomal dominant form of skeletal dysplasia caused by 
gain-of-function mutation of the FGFR3 gene.10 ACH is the most common form of non-lethal 
skeletal dysplasia with a prevalence of ~1/25,000 live births.11 Characteristic features include an 
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(rhizomelia), and macrocephaly with a prominent forehead. There is a characteristic hand 
phenotype in that fingers are typically short (brachydactyly) and the ring finger and middle 
finger may diverge, giving the hand a three-pronged (trident) appearance. Individuals with 
Achondroplasia are not predisposed to decreased bone density and do not have a predisposition 
to fracture.   
Osteogenesis Imperfecta (OI) is a heritable connective tissue disorder characterized by 
bone and tissue fragility. Osteogenesis Imperfecta (OI) occurs in approximately 1/10,000 live 
births.12 The majority of cases result from dominant mutations of the COL1a1 or COL1a2 genes, 
although less common, mostly recessive forms result from mutations affecting proteins 
associated with collagen processing and trafficking.13 (13) Clinical severity and phenotypic 
presentation ranges widely, from perinatal lethality (type II) to mild disease (type I). 
Phenotypically, even patients with more severe types of OI tend to have hands which fall within 
morphologic norms for non-skeletal dysplasia populations. The most common treatments for OI 
are surgical rodding14 and bisphosphonate treatment12.       
 This study aims to calculate robustness from measurements of the second metacarpal of 
patients with ACH, OI, and average-statured individuals in order to characterize the pattern of 
bone morphology and to identify differences in growth patterns that may inform clinicians on 
how to best treat these diseases. We hypothesize that: 1) patients with ACH will have more 
robust bones than average-statured patients, 2) OI patients will have similar robustness to 
average-statured patients, and 3) that bisphosphonate treatment will not impact bone robustness 
for OI patients. 
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This is an IRB-approved retrospective review (evidence level 3) of bone age films (AP 
hand/wrist). A total of 169 de-identified digital bone age films were reviewed and measured 
using Sectra IDS 7 PACS (Sectra AB, Linköping, Sweden). Measurements included: second 
metacarpal length (Le), proximal to distal end; and marrow diameters (Ma.Dm, distance between 
inner cortices) and outer bone diameters (B.Dm, distance between outer cortices) measured at 
30%, 40%, 50%, and 60% of the total metacarpal length. Total cross sectional area (R2, R = 
outer bone diameter/2), cortical area (total area - marrow area), marrow area (πr2 (r = inner bone 
diameter/2), polar moment of inertia (π/2 (R4 - r4)), robustness (Total Area / Bone Length), and 
relative cortical area (RCA, cortical area /total area) were calculated to analyze metacarpal size 
and to estimate strength.  
Twenty individuals with Achondroplasia (5 months-58 years), 39 patients with OI (1 year 
9 months- 67 years) and 37 modern controls (4 year 6 months-21 years) were included in this 
study. Their demographic data derived from chart review are in Table I. This sample of modern 
controls (diagnosed with leg length discrepancy) matched historical measurements from the 
Bolton-Brush Collection (ages 3 months to 16 years). Chronological age, as opposed to bone-
age, was used to compare groups given that standard growth curves have been established for 
controls, but not for the Achondroplasia or OI populations. Non-parametric Kruskal-Wallis tests 
were used to compare differences in bone characteristics between study groups with statistical 
significance accepted at p≤0.05. 
Table I: Place here, please. 
Results  
Individuals with ACH had robustness values above (p<.0.001) and relative cortical area 
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phenotype was consistent with the reduced longitudinal metacarpal growth seen in ACH. ACH 
cortices tended to be thinner (p<.0.001) than those of the control population. Sexual dimorphism 
in robustness (p<0.01) and RCA values (p<0.05) were found in ACH, similar to that reported in 
the unaffected population.  
RCA values for individuals with OI were higher than the control group (p<.0.001) and OI 
displayed decreased robustness across all types (p<.0.001) (Figure I-a, b). Individuals with OI 
fell into the most slender tertile for robustness of the control population (Table II) and had no 
increase in absolute cortical thickness averages compared to control population. Sexual 
dimorphism was not significant for either robustness or RCA. 
Figure I: Place here, please 
Table II: place here, please.  
 
Nineteen of the 39 individuals with OI (17 males, 22 females) received bisphosphonate 
treatment ±2 years of their bone age X-ray. This included 28.6% of OI Type I (4/14), 75% of OI 
Type III (9/12), 50% of OI Type V (1/2); 100% of OI Type VIII (1/1); 50% of OI Type IX (1/2); 
100% of unknown recessive OI (2/2), and 42.9% of OI Type IV(2/7). There were no significant 
differences in robustness and RCA between treated and non-treated individuals. All had 
robustness values below and RCA values above the control population. 
Discussion 
This is the first study of bone robustness in two skeletal dysplasia populations, 
Achondroplasia and OI. Understanding the changes in bone surfaces (periosteal, endosteal) 
individually and relative to each other provides important insight into the structural basis of the 
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ACH. We also considered the effects of bisphosphonate treatment on bone morphology in OI, 
which has not been done before.  
This study shows that the ACH population has a pattern of more robust bones compared 
to control populations, while the OI population tended to be slightly less robust compared to 
control populations. The inverse relationship between robustness and RCA for the ACH and OI 
populations was consistent with the control populations. The increased metacarpal length in 
patients with OI compared to patients with ACH (p<.0.001) suggests that differences in 
robustness between the two can be attributed in part to the difference in longitudinal metacarpal 
growth (Table II).  
The reduced bone mass of OI seems to come from suppressed periosteal expansion 
(lower Tt.Ar) and not failure to accumulate bone mass, given that RCA was appropriate for 
slender phenotype. The lack of increase in absolute cortical thickness averages in OI does not 
follow the expected pattern seen in the control population, but may be consistent with bone 
fragility characteristic of OI. Because slender bones are structurally weaker than wide bones, 
individuals with OI, therefore, have both a material and structural problem contributing to their 
overall strength deficit. Further, the lack of sexual dimorphism in the OI population is in contrast 
to that reported in unaffected populations8. Given the mechanistic link between type 1 collagen 
and bone strength, we suggest that the underlying collagen abnormalities in OI may override sex-
specific effects on bone development. In general, slender bones rely on osteoblasts for new bone 
deposition, whereas robust bones rely on osteoclasts for continued marrow expansion during 
growth. Therefore, it is not surprising that bisphosphonate treatment, which affects osteoclasts 
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individuals with OI. These findings suggest that future treatments for OI should focus on 
periosteal expansion (not suppressing resorption) to strengthen long bones. 
The very robust bones of the ACH population arise from suppressed longitudinal growth. 
Lower than expected RCA for the increased robustness, suggests ACH patients fail to 
accumulate sufficient bone mass (Ct.Ar). Presumably, the reduced RCA comes from excessive 
marrow space expansion (almost no difference in Ma.Ar between ACH and control). Sexual 
dimorphism was found in both robustness and RCA for the ACH patients in this study, 
suggesting that without the dual material and structural problem of OI, this patient population 
retains the sexual dimorphism reported in unaffected populations. Treatment for individuals with 
ACH developing osteoporosis should focus on targeting marrow space expansion.  
This study lays the groundwork for analysis of potential treatments and their effect on 
bone morphology both in OI and other osteopenic/osteoporotic populations, as well as in 
Achondroplasia and other forms of dwarfism. The x-rays measured in this study were taken as a 
standard-of-care measure, but there is always a concern about radiation exposure. These 
disparate growth patterns would be expected to result in different responses to clinical treatments 
(anabolic versus anti-catabolic), depending on sex, age, and robustness. Although measurements 
conducted by different researchers were tested and found to have statistically insignificant 
differences, there remains potential for inter-measurer discrepancies. A larger sample size is 
needed to ensure the reliability of population means and confirm the trends observed. 
Specifically, additional studies are needed to test whether the underlying collagen abnormalities 
in OI override sex-specific effects on bone strength and development. In addition, a larger 
sample size and additional longitudinally acquired x-rays for individual patients would allow for 
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genetic and environmental factors define the variation in subperiosteal expansion relative to 
longitudinal growth by 2 years of age in unaffected populations.8 Additional patients will allow 
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Figure I: Individual patient measurements for Achondroplasia and Osteogenesis Imperfecta. 
Plots compare Tt.Ar/Le or robustness (a, d) and Ct.Ar/Tt.Ar or RCA (b, e) by diagnosis across 
chronological age against control values. RCA plotted by sex and diagnosis across chronological 
age (c, f). 
Table I: Demographic data for the three study populations. 
      
 
  Total (n) Male Female 
 
 
Achondroplasia 20 10 10 
 
 
OI (All types) 39 17 22 
 
 
  OI Type I 14 4 10 
 
 
  OI Type III 12 6 6 
 
 
  OI Type IV 7 5 2 
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  OI Type VIII 1 0 1 
 
 
  OI Type IX 3 1 1 
 
 
  OI Unknown Recessive 1 0 1 
 
 
Control 37 22 15 
 
       
Table II: Average measurements and calculations for second metacarpal (mean ± stdev) reported for 
total (males and females), males, and females; all ages included by diagnosis.  
 
  Control  ACH   
 
  Total Male Female Total Male Female    
 
Le. (mm) 56.8 ± 9.43 60.0 ± 8.81 53.6 ± 9.06 28.9 ± 14.8 29.6 ± 14.9 28.2 ± 14.2          
 
Tt.Ar (mm2) 40.4 ± 11.5 44.2 ± 11.5 35.5 ± 9.48 27.9 ± 12.8 28.9 ± 11.6 25.7 ± 14.5          
 
Ct.Ar (mm2) 27.7 ± 8.36 31.2 ± 8.25 24.2 ± 6.97 16.5 ± 11.6 16.4 ± 10.8 16.3 ± 12.7          
 
Marrow Area (mm2) 12.7 ± 4.20 14.0 ± 4.38 11.4 ± 3.57 11.4 ± 5.60 12.5 ± 5.90 9.33 ± 5.02          
 
Polar Moment of Inertia 
(mm4) 253 ± 141 311 ± 149 192 ± 103 124 ± 135 122 ± 117 119 ± 160         
 
Cortical Thickness (mm) 1.57 ± 0.31 1.67 ± 0.29 1.45 ± 0.28 1.05 ± 0.59 1.03 ± 0.59 1.10 ± 0.61          
 
RCA 0.68 ± 0.05 0.69 ± 0.05 0.68 ± 0.05 0.57 ± 0.16 0.54 ± 0.17 0.60 ± 0.14          
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Abstract 
Achondroplasia is a heritable disorder of endochondral bone formation characterized by 
disproportionate short stature. Osteogenesis imperfecta is a heritable bone and connective tissue 
disorder characterized by bone fragility. To investigate bone morphology of these groups, we 
retrospectively reviewed 169 de-identified bone age films from 20 individuals with 
achondroplasia, 39 individuals with osteogenesis imperfecta and 37 age- and sex-matched 
controls (matched to historical measurements from the Bolton-Brush Collection). We calculated 
robustness (Tt.Ar/Le) and relative cortical area (Ct.Ar/Tt.Ar) from measurements of the second 
metacarpal, which reflect overall bone health. Relative cortical area is a significant predictor of 
fracture risk and correlates with robustness at other sites. Individuals with osteogenesis 
imperfecta had relative cortical area values above and robustness values below that of the control 
population. Bisphosphonate treatment did not significantly impact either robustness or relative 
cortical area. In contrast to that reported in the unaffected population, there was no sexual 
dimorphism found in osteogenesis imperfecta robustness or relative cortical area. We suggest 
that the underlying collagen abnormalities in osteogenesis imperfecta override sex-specific 
effects. Individuals with achondroplasia had robustness values above and relative cortical area 
values below that of the control population. Sexual dimorphism was found in achondroplasia 
robustness and relative cortical area values. Clinical significance:  Identifies morphologic trends 
in two distinct skeletal dysplasia populations (osteogenesis imperfecta and achondroplasia) to 
better understand development of bone robusticity and slenderness in humans. Understanding 
these patterns of bone morphology is important to predict how individuals will respond to 
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Introduction 
Variation in morphologic parameters (e.g. bone length and width) contributes to the 
stiffness and strength of the skeleton. Robusticity (total area/bone length) is a trait that describes 
the relationship between transverse expansion and longitudinal growth in long bones (i.e. 
expansion at the growth plate versus periosteal growth)1. The second metacarpal, which has been 
used to determine overall bone health since the 1960s2, has multiple muscle attachments that 
apply sufficient forces to establish mechanically functional structures with varying robustness 
through compensatory changes in morphology 3. Additionally, the second metacarpal has been 
shown to be a significant predictor of fracture risk at the hip4 and vertebrae5 and its robustness 
has been correlated with that at other sites, i.e. femur and tibia 6, 7.    
 Ideally, bones which fall towards the very robust end of the spectrum compensate by 
having a proportionally thinner cortex to minimize mass3. Therefore, robust bones should have a 
low mineral content. Bones which fall toward the narrow or slender end of the external size 
spectrum compensate by having a proportionally thicker cortex to maximize stiffness and 
strength. Therefore, slender bones should have a higher mineral content. The relationship 
between external bone size and relative cortical area and tissue-mineral density is an adaptive 
biological process that involves bone cells adjusting traits (e.g., cortical area, mineralization) in a 
highly coordinated manner so the resultant set of traits has sufficient stiffness to support the 
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We postulate that the adaptation process during growth varies in fundamentally different 
ways among individuals, which results in the acquisition of specific sets of traits that are 
predictable based on bone robustness. Because homeostatic buffering mechanisms during growth 
control the degree of compensation that can be expressed in a population, we expect that 
genetically heterogeneous individuals would not show random trait sets (length, external size, 
internal size), but rather a narrow range of functionally adapted sets of traits. This has been 
confirmed in a recent study using hand radiographs purchased from the Bolton-Brush collection. 
The Bolton-Brush collection includes 330 longitudinally acquired hand radiographs from 24 
healthy white girls and 31 healthy white boys collected in the 1930s in Cleveland, OH. 8 That 
research demonstrated that the inter-individual variation in bone robustness was largely 
determined by 2 years of age. There was a sex-specific difference in that prepubertal girls had 
more slender metacarpals with proportionally thicker cortices compared with prepubertal boys. 
Boys and girls with robust diaphyses had proportionally thinner cortices, thereby minimizing 
overall mass, whereas children with slender diaphyses had proportionally thicker cortices to 
maximize stiffness8 consistent with weight-bearing long bones1.    
 Finding a consistent pattern of trait sets across a population is important, because it 
means that individuals within this population share a common biological control which regulates 
functional adaptation. Further, finding a consistent pattern of trait sets across a population 
suggests that we can use these biomechanically-based methods to identify, in a new way, disease 
states or treatments that potentially alter the development of bone strength.   
Specifically, understanding the biological factors and variation in these parameters in two 
disparate skeletal dysplasias should allow a better understanding of the inter-individual variation 








This article is protected by copyright. All rights reserved 
non-dysplastic population. The skeletal dysplasias comprise a clinically and genetically 
heterogeneous group of over 400 disorders associated with abnormal bone and cartilage growth 
and development9. The two skeletal dysplasias in this study are achondroplasia and osteogenesis 
imperfecta. We selected these diagnoses because of their relatively high prevalence, 
comparatively different clinical findings, and distinct skeletal phenotypes.    
Achondroplasia (ACH) is an autosomal dominant form of skeletal dysplasia caused by 
gain-of-function mutation of the FGFR3 gene.10 ACH is the most common form of non-lethal 
skeletal dysplasia with a prevalence of ~1/25,000 live births.11 Characteristic features include an 
average-size trunk, short arms and legs with particularly short upper arms and thighs 
(rhizomelia), and macrocephaly with a prominent forehead. There is a characteristic hand 
phenotype in that fingers are typically short (brachydactyly) and the ring finger and middle 
finger may diverge, giving the hand a three-pronged (trident) appearance. Individuals with 
Achondroplasia are not predisposed to decreased bone density and do not have a predisposition 
to fracture.   
Osteogenesis Imperfecta (OI) is a heritable connective tissue disorder characterized by 
bone and tissue fragility. Osteogenesis Imperfecta (OI) occurs in approximately 1/10,000 live 
births.12  The majority of cases result from dominant mutations of the COL1a1 or COL1a2 genes, 
although less common, mostly recessive forms result from mutations affecting proteins 
associated with collagen processing and trafficking.13 (13) Clinical severity and phenotypic 
presentation ranges widely, from perinatal lethality (type II) to mild disease (type I). 
Phenotypically, even patients with more severe types of OI tend to have hands which fall within 
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are surgical rodding14 and bisphosphonate treatment12.       
 This study aims to calculate robustness from measurements of the second metacarpal of 
patients with ACH, OI, and average-statured individuals in order to characterize the pattern of 
bone morphology and to identify differences in growth patterns that may inform clinicians on 
how to best treat these diseases. We hypothesize that: 1) patients with ACH will have more 
robust bones than average-statured patients, 2) OI patients will have similar robustness to 
average-statured patients, and 3) that bisphosphonate treatment will not impact bone robustness 
for OI patients. 
Patients and Methods 
This is an IRB-approved retrospective review (evidence level 3) of bone age films (AP 
hand/wrist). A total of 169 de-identified digital bone age films were reviewed and measured 
using Sectra IDS 7 PACS (Sectra AB, Linköping, Sweden). Measurements included: second 
metacarpal length (Le), proximal to distal end; and marrow diameters (Ma.Dm, distance between 
inner cortices) and outer bone diameters (B.Dm, distance between outer cortices) measured at 
30%, 40%, 50%, and 60% of the total metacarpal length.  Total cross sectional area (R2, R = 
outer bone diameter/2), cortical area (total area - marrow area), marrow area (πr2 (r = inner bone 
diameter/2), polar moment of inertia (π/2 (R4 - r4)), robustness (Total Area / Bone Length), and 
relative cortical area (RCA, cortical area /total area) were calculated to analyze metacarpal size 
and to estimate strength.  
Twenty individuals with Achondroplasia (5 months-58 years), 39 patients with OI (1 year 
9 months- 67 years) and 37 modern controls (4 year 6 months-21 years) were included in this 
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controls (diagnosed with leg length discrepancy) matched historical measurements from the 
Bolton-Brush Collection (ages 3 months to 16 years). Chronological age, as opposed to bone-
age, was used to compare groups given that standard growth curves have been established for 
controls, but not for the Achondroplasia or OI populations. Non-parametric Kruskal-Wallis tests 
were used to compare differences in bone characteristics between study groups with statistical 
significance accepted at p≤0.05. 
Table I: Place here, please. 
Results   
Individuals with ACH had robustness values above (p<.0.001) and relative cortical area 
(RCA) values below (p<.0.001) that of the control population (Figure I-a, b). This robust 
phenotype was consistent with the reduced longitudinal metacar al growth seen in ACH. ACH 
cortices tended to be thinner (p<.0.001) than those of the control population. Sexual dimorphism 
in robustness (p<0.01) and RCA values (p<0.05) were found in ACH, similar to that reported in 
the unaffected population.   
RCA values for individuals with OI were higher than the control group (p<.0.001) and OI 
displayed decreased robustness across all types (p<.0.001) (Figure I-a, b). Individuals with OI 
fell into the most slender tertile for robustness of the control population (Table II) and had no 
increase in absolute cortical thickness averages compared to control population. Sexual 
dimorphism was not significant for either robustness or RCA. 
Figure I: Place here, please 
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Nineteen of the 39 individuals with OI (17 males, 22 females) received bisphosphonate 
treatment ±2 years of their bone age X-ray. This included 28.6% of OI Type I (4/14), 75% of OI 
Type III (9/12), 50% of OI Type V (1/2); 100% of OI Type VIII (1/1); 50% of OI Type IX (1/2); 
100% of unknown recessive OI (2/2), and 42.9% of OI Type IV(2/7). There were no significant 
differences in robustness and RCA between treated and non-treated individuals. All had 
robustness values below and RCA values above the control population. 
Discussion 
This is the first study of bone robustness in two skeletal dysplasia populations, 
Achondroplasia and OI.  Understanding the changes in bone surfaces (periosteal, endosteal) 
individually and relative to each other provides important insight into the structural basis of the 
strength deficits that may indicate how and when to treat to improve bone strength in OI and 
ACH.  We also considered the effects of bisphosphonate treatment on bone morphology in OI, 
which has not been done before.  
This study shows that the ACH population has a pattern of more robust bones compared 
to control populations, while the OI population tended to be slightly less robust compared to 
control populations. The inverse relationship between robustness and RCA for the ACH and OI 
populations was consistent with the control populations. The increased metacarpal length in 
patients with OI compared to patients with ACH (p<.0.001) suggests that differences in 
robustness between the two can be attributed in part to the difference in longitudinal metacarpal 
growth (Table II).  
The reduced bone mass of OI seems to come from suppressed periosteal expansion 
(lower Tt.Ar) and not failure to accumulate bone mass, given that RCA was appropriate for 
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follow the expected pattern seen in the control population, but may be consistent with bone 
fragility characteristic of OI. Because slender bones are structurally weaker than wide bones, 
individuals with OI, therefore, have both a material and structural problem contributing to their 
overall strength deficit. Further, the lack of sexual dimorphism in the OI population is in contrast 
to that reported in unaffected populations8. Given the mechanistic link between type 1 collagen 
and bone strength, we suggest that the underlying collagen abnormalities in OI may override sex-
specific effects on bone development. In general, slender bones rely on osteoblasts for new bone 
deposition, whereas robust bones rely on osteoclasts for continued marrow expansion during 
growth. Therefore, it is not surprising that bisphosphonate treatment, which affects osteoclasts 
more than osteoblasts, did not appreciably change morphologic parameters in the diaphyses of 
individuals with OI. These findings suggest that future treatments for OI should focus on 
periosteal expansion (not suppressing resorption) to strengthen long bones. 
The very robust bones of the ACH population arise from suppressed longitudinal growth. 
Lower than expected RCA for the increased robustness, suggests ACH patients fail to 
accumulate sufficient bone mass (Ct.Ar). Presumably, the reduced RCA comes from excessive 
marrow space expansion (almost no difference in Ma.Ar between ACH and control). Sexual 
dimorphism was found in both robustness and RCA for the ACH patients in this study, 
suggesting that without the dual material and structural problem of OI, this patient population 
retains the sexual dimorphism reported in unaffected populations. Treatment for individuals with 
ACH developing osteoporosis should focus on targeting marrow space expansion.  
This study lays the groundwork for analysis of potential treatments and their effect on 
bone morphology both in OI and other osteopenic/osteoporotic populations, as well as in 
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standard-of-care measure, but there is always a concern about radiation exposure. These 
disparate growth patterns would be expected to result in different responses to clinical treatments 
(anabolic versus anti-catabolic), depending on sex, age, and robustness. Although measurements 
conducted by different researchers were tested and found to have statistically insignificant 
differences, there remains potential for inter-measurer discrepancies. A larger sample size is 
needed to ensure the reliability of population means and confirm the trends observed. 
Specifically, additional studies are needed to test whether the underlying collagen abnormalities 
in OI override sex-specific effects on bone strength and development.  In addition, a larger 
sample size and additional longitudinally acquired x-rays for individual patients would allow for 
observation of any aging effect on bone growth patterns in OI and ACH populations. Lastly, 
genetic and environmental factors define the variation in subperiosteal expansion relative to 
longitudinal growth by 2 years of age in unaffected populations.8  Additional patients will allow 
validation of this in the dysplastic populations. 
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Legends List: 
Table I: Demographic data for the three study populations. 
 
Figure I: Individual patient measurements for Achondroplasia and Osteogenesis Imperfecta. 
Plots compare Tt.Ar/Le or robustness (a, d) and Ct.Ar/Tt.Ar or RCA (b, e) by diagnosis across 
chronological age against control values. RCA plotted by sex and diagnosis across chronological 
age (c, f). 
Table II: Average measurements and calculations for second metacarpal (mean ± stdev) 
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Raggio Metacarpal Figure . 
 
